Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer.
Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer.
复制标题
DOI：
10.1158/0008-5472.can-16-2355
复制
发表时间：
2017-06-15
期刊：
影响因子：
11.2
通讯作者：
Mahato RI
中科院分区：
文献类型：
--
作者：
Wen D;Peng Y;Lin F;Singh RK;Mahato RI
Treatment of prostate cancer with paclitaxel (PTX) often fails due to development of chemoresistance caused by downregulation of the tumor suppressor gene miR-34a. In this study, we demonstrate that co-delivery of PTX and 2'-hydroxy-2,4,4',5,6'-pentamethoxychalcone (termed rubber) drives upregulation of miR-34a and chemosensitizes PTX-resistant prostate cancer cells, killing both cancer stem-like cells (CSCs) and bulk tumor cells. Rubone上调了MiR-34a，并在DU145-TXR和PC3-TXR细胞中扭转了其下游靶基因，Rubone Compination Therapy抑制了肿瘤细胞的生长，迁移和CSC种群的生长。药物负载能力为9.70±0.10％和5.34± PTX和Rubone的0.02％在24小时内释放了60.20±2.67％和60.62±4.35％的PTX和rubone。分别为55.6和2580 nm，但下降到49.8和93.2 nm与橡胶结合使用，证明了Rubone的PTX耐药性，与Mir-34a，Cyclin D1相比，与单位疗法相比，携带PTX和Rubone的胶束抑制了裸鼠的原位前列腺肿瘤的生长。 miR-34a的ULE调节器逆转化学耐药性并进一步提高了PTX对PTX耐药性前列腺癌的治疗效率。
Treatment of prostate cancer with paclitaxel (PTX) often fails due to development of chemoresistance caused by downregulation of the tumor suppressor gene miR-34a. In this study, we demonstrate that co-delivery of PTX and 2′-hydroxy-2,4,4′,5,6′-pentamethoxychalcone (termed rubone) drives upregulation of miR-34a and chemosensitizes PTX-resistant prostate cancer cells, killing both cancer stem-like cells (CSCs) and bulk tumor cells. Rubone upregulated miR-34a and reversed its downstream target genes in DU145-TXR and PC3-TXR cells. PTX and rubone combination therapy inhibited tumor cell growth, migration, and CSC population growth. We synthesized poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene carbonate-graft-dodecanol) (PEG-PCD) to prepare micelles. The drug-loading capacities were 9.70 ± 0.10% and 5.34 ± 0.02% for PTX and rubone, respectively, controlling a drug release of 60.20 ± 2.67% and 60.62 ± 4.35% release of PTX and rubone at 24 h. Delivery of miR-34a and rubone decreased PC3-TXR cell viability with increasing PTX concentration. Co-incubation with a miR-34a inhibitor diminished the effect of rubone. PTX IC50 in PC3 and PC3-TXR cells was 55.6 and 2580 nM, respectively, but decreased to 49.8 and 93.2 nM when treated in combination with rubone, demonstrating a reversal of PTX resistance by rubone. Systemic administration of micelles carrying PTX and rubone inhibited orthotopic prostate tumor growth in nude mice, compared to monotherapy, by reversing the expression of miR-34a, SIRT1, Cyclin D1 and E-cadherin. In summary, our results showed how rubone acts as an efficient small molecule modulator of miR-34a to reverse chemoresistance and further enhance the therapeutic efficacy of PTX in PTX-resistant prostate cancer.